Tags : T2D Adults

Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval to

Vartika Singh February 24, 2020

Shots: The approval follows the REWIND study which involves assessing of Trulicity + SoC (1.5mg) vs PBO + SoC in adults with T2D The study showed reduction in MACE events […]readmore

Tags : T2D Adults

Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : T2D Adults

Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company